Autoantibody-mediated dysfunction of sympathetic neurons in Guillain-Barré syndrome

Archives of Neurology

Volumn 67, Issue 2, 2010, Pages 203-210

  Lehmann, Helmar C ^a   Jangouk, Parastoo ^a   Kierysch, Eva K ^a   Meyer Zu Hörste, Gerd ^a   Hartung, Hans Peter ^a   Kieseier, Bernd C ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CELL ANTIBODY; IMMUNOGLOBULIN G; NORADRENALIN; TYROSINE 3 MONOOXYGENASE;

ADULT; AGED; ARTICLE; AUTONOMIC DYSFUNCTION; AUTONOMIC NERVE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; COCULTURE; CONTROLLED STUDY; FEMALE; GUILLAIN BARRE SYNDROME; HEART CELL CULTURE; HUMAN; HUMAN CELL; MALE; MULTIPLE SCLEROSIS; NERVE CELL CULTURE; PRIORITY JOURNAL; SYMPATHETIC NERVE CELL; SYNAPTIC TRANSMISSION; UPREGULATION;

ACTINS; ADULT; AGED; ANIMALS; ANIMALS, NEWBORN; COCULTURE TECHNIQUES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYOCYTES, CARDIAC; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; RATS; RNA, MESSENGER; SENSORY RECEPTOR CELLS; SUPERIOR CERVICAL GANGLION; TYROSINE 3-MONOOXYGENASE; VAGUS NERVE;

EID: 76149087432     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2009.331     Document Type: Article

References (53)

1. Flachenecker P. Autonomic dysfunction in Guillain-Barre syndrome and multiple sclerosis. J Neurol. 2007;254(suppl 2):II96-II101.
2. Hughes RA, Cornblath DR. Guillain-Barre syndrome. Lancet. 2005;366(9497):1653-1666.
3. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barre syndrome. Lancet Neurol. 2008;7(10):939-950.
4. Zochodne DW. Autonomic involvement in Guillain-Barre syndrome: a review. Muscle Nerve. 1994;17(10):1145-1155.
5. Kieseier BC, Kiefer R, Gold R, Hemmer B, Willison HJ, Hartung HP. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve. 2004;30(2):131-156.
6. Flachenecker P, Hartung HP, Reiners K. Power spectrum analysis of heart rate variability in Guillain-Barre syndrome. Brain. 1997;120(pt 10):1885-1894.
7. Yamamoto K, Sobue G, Iwase S, Nagamatsu M, Mano T, Mitsuma T. Skin sympathetic nerve activity in Guillain-Barre syndrome: a microneurographic study. J Neurol Neurosurg Psychiatry. 1997;63(4):537-541.
8. Birchfield RI, Shaw CM. Postural hypotension in the Guillain-Barre syndrome. Arch Neurol. 1964;10:149-157.
9. Matsuyama H, Haymaker W. Distribution of lesions in the Landry-Guillain-Barre syndrome with emphasis on involvement of the sympathetic system. Acta Neuropathol. 1967;8(3):230-241.
10. Hartung HP, Willison HJ, Kieseier BC. Acute immunoinflammatory neuropathy: update on Guillain-Barre syndrome. Curr Opin Neurol. 2002;15(5):571-577.
11. Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain. 2002;125(pt 12):2591-2625.
12. Hughes RA, Gray IA, Gregson NA, et al. Immune responses to myelin antigens in Guillain-Barre syndrome. J Neuroimmunol. 1984;6(5):303-312.
13. Buchwald B, Toyka KV, Zielasek J, Weishaupt A, Schweiger S, Dudel J. Neuromuscular blockade by IgG antibodies from patients with Guillain-Barre syndrome: a macro-patch-clamp study. Ann Neurol. 1998;44(6):913-922.
14. Saida T, Saida K, Lisak RP, Brown MJ, Silberberg DH, Asbury AK. In vivo demyelinating activity of sera from patients with Guillain-Barre syndrome. Ann Neurol. 1982;11(1):69-75.
15. Krampfl K, Mohammadi B, Buchwald B, et al. IgG from patients with Guillain-Barre syndrome interact with nicotinic acetylcholine receptor channels. Muscle Nerve. 2003;27(4):435-441.
16. Buchwald B, Bufler J, Carpo M, et al. Combined pre- and postsynaptic action of IgG antibodies in Miller Fisher syndrome. Neurology. 2001;56(1):67-74.
17. Demestre M, Pullen A, Orrell R, Orth M. ALS-IgG-induced selective motor neurone apoptosis in rat mixed primary spinal cord cultures. J Neurochem. 2005; 94(1):268-275.
18. Wang Z, Low P, Jordan J, et al. Autoimmune autonomic ganglionopathy. Neurology. 2007;68(22):1917-1921.
19. Lockhart ST, Turrigiano GG, Birren SJ. Nerve growth factor modulates synaptic transmission between sympathetic neurons and cardiac myocytes. J Neurosci. 1997;17(24):9573-9582.
20. Yang B, Slonimsky JD, Birren SJ. A rapid switch in sympathetic neurotransmitter release properties mediated by the p75 receptor. Nat Neurosci. 2002;5(6):539-545.
21. Kan H, Xie Z, Finkel M. Norepinephrine-stimulated MAP kinase activity enhances cytokine-induced NO production by rat cardiac myocytes. Am J Physiol. 1999;276(1, pt 2):H47-52.
22. Kopadze T, Dehmel T, Hartung HP, Stuve O, Kieseier BC. Inhibition by mitoxantrone of in vitro migration of immunocompetent cells. Arch Neurol. 2006;63 (11):1572-1578.
23. Kuhar MJ, Couceyro PR, Lambert PD. Catecholamines. Vol 2. 6th ed. Philadelphia, PA: Lippincott, Wilkins and Williams; 1999.
24. Arvidsson U, Riedl M, Elde R, Meister B. Vesicular acetylcholine transporter (VAChT) protein. J Comp Neurol. 1997;378(4):454-467.
25. van Doorn PA, Brand A, Vermeulen M. Anti-neuroblastoma cell line antibodies in inflammatory demyelinating polyneuropathy. Neurology. 1988;38(10):1592-1595.
26. Buchwald B, Weishaupt A, Toyka KV, Dudel J. Immunoglobulin G from a patient with Miller-Fisher syndrome rapidly and reversibly depresses evoked quantal release at the neuromuscular junction of mice. Neurosci Lett. 1995;201(2):163-166.
27. Buchwald B, Weishaupt A, Toyka KV, Dudel J. Pre- and postsynaptic blockade of neuromuscular transmission by Miller-Fisher syndrome IgG at mouse motor nerve terminals. Eur J Neurosci. 1998;10(1):281-290.
28. Hartung HP, Kieseier BC, Kiefer R. Progress in Guillain-Barre syndrome. Curr Opin Neurol. 2001;14(5):597-604.
29. Kieseier BC, Wiendl H, Hartung HP. The inflamed peripheral nervous system: update on immune therapies. Curr Opin Neurol. 2006;19(5):433-436.
30. Vernino S, Ermilov L, Sha L, Szurszewski J, Low P, Lennon V. Passive transfer of autoimmune autonomic neuropathy to mice. J Neurosci. 2004;24(32):7037-7042.
31. Vernino S, Low P, Lennon V. Experimental autoimmune autonomic neuropathy. J Neurophysiol. 2003;90(3):2053-2059.
32. Waterman SA, Lang B, Newsom-Davis J. Effect of Lambert-Eaton myasthenic syndrome antibodies on autonomic neurons in the mouse. Ann Neurol. 1997; 42(2):147-156.
33. Kirvan CA, Swedo SE, Heuser JS, Cunningham MW. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat Med. 2003;9(7): 914-920.
34. Zigmond RE, Schwarzschild MA, Rittenhouse AR. Acute regulation of tyrosine hydroxylase by nerve activity and by neurotransmitters via phosphorylation. Annu Rev Neurosci. 1989;12:415-461.
35. Waterman SA. Voltage-gated calcium channels in autonomic neuroeffector transmission. Prog Neurobiol. 2000;60(2):181-210.
36. Halstead SK, Zitman FM, Humphreys PD, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain. 2008; 131(pt 5):1197-1208.
37. Halstead SK, Humphreys PD, Goodfellow JA, Wagner ER, Smith RA, Willison HJ. Complement inhibition abrogates nerve terminal injury in Miller Fisher syndrome. Ann Neurol. 2005;58(2):203-210.
38. Goodfellow JA, Bowes T, Sheikh K, et al. Overexpression of GD1a ganglioside sensitizes motor nerve terminals to anti-GD1a antibody-mediated injury in a model of acute motor axonal neuropathy. J Neurosci. 2005;25(7):1620-1628.
39. Yuki N, Susuki K, Koga M, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc Natl Acad Sci U S A. 2004;101(31):11404- 11409.
40. Yuki N, Yamada M, Koga M, et al. Animal model of axonal Guillain-Barre syndrome induced by sensitization with GM1 ganglioside. Ann Neurol. 2001;49 (6):712-720.
41. Lehmann HC, Lopez PH, Zhang G, et al. Passive immunization with anti-ganglioside antibodies directly inhibits axon regeneration in an animal model. J Neurosci. 2007;27(1):27-34.
42. Lehmann HC, Hartung HP. Complementing the therapeutic armamentarium for Miller Fisher Syndrome and related immune neuropathies. Brain. 2008;131 (pt 5):1168-1170.
43. Asahina M, Kuwabara S, Suzuki A, Hattori T. Autonomic function in demyelinating and axonal subtypes of Guillain-Barre syndrome. Acta Neurol Scand. 2002; 105(1):44-50.
44. Flachenecker P, Wermuth P, Hartung HP, Reiners K. Quantitative assessment of cardiovascular autonomic function in Guillain-Barre syndrome. Ann Neurol. 1997; 42(2):171-179.
45. Abend NS, Bonnemann CG, Licht DJ. Status epilepticus secondary to hypertensive encephalopathy as the presenting manifestation of Guillain-Barre syndrome. Pediatr Emerg Care. 2007;23(9):659-661.
46. Cochen V, Arnulf I, Demeret S, et al. Vivid dreams, hallucinations, psychosis and REM sleep in Guillain-Barre syndrome. Brain. 2005;128(pt 11):2535-2545.
47. Ahmad J, Kham AS, Siddiqui MA. Estimation of plasma and urinary catecholamines in Guillain-Barre syndrome. Jpn J Med. 1985;24(1):24-29.
48. Ventura HO, Messerli FH, Barron RE. Norepinephrine-induced hypertension in Guillain Barre syndrome. J Hypertens. 1986;4(3):265-267.
49. Yao H, Fukiyama K, Takada Y, Fujishima M, Omae T. Neurogenic hypertension in the Guillain-Barre syndrome. Jpn Heart J. 1985;26(4):593-596.
50. Weiss H, Rastan V, Mullges W, Wagner RF, Toyka KV. Psychotic symptoms and emotional distress in patients with Guillain-Barre syndrome. Eur Neurol. 2002; 47(2):74-78.
51. Van Diest D, Van Goethem J, Vercruyssen A, Jadoul C, Cras P. Posterior reversible encephalopathy and Guillain-Barré syndrome in a single patient: coincidence or causative relation? Clin Neurol Neurosurg. 2007;109(1):58-62.
52. Okada T, Hiyoshi K, Noto N, et al. A case of Guillain-Barré syndrome accompanied by sympathetic overactivity and hypertensive encephalopathy. Acta Paediatr. 1996;85(8):1006-1008.
53. Ishitobi M, Haginoya K, Kitamura T, Munakata M, Yokoyama H, Iinuma K. Acute dysautonomia. Brain Dev. 2004;26(8):542-544.